Table 3 Potential factors related to clinical effectiveness
Characteristic | Effective group (n = 10) | Ineffective group (n = 19) | p value |
|---|---|---|---|
Male/female (n, %) | 2 (20.0%)/8 (80.0%) | 12 (63.2%)/7 (36.8%) | 0.050 |
Age (years) (median [IQR]) | 17.5 (15.5, 24.5) | 20 (16, 25) | 0.662 |
Course of disease (months) (median [IQR]) | 132 (81, 198) | 120 (60, 180) | 0.836 |
AChR-Ab positivity (n, %) | 7 (70.0%) | 14 (73.7%) | 1.000 |
AChR-Ab titer (nmol/L) (median [IQR]) | 0.67 (0.50, 10.83) | 0.90 (0.51, 4.76) | 0.850 |
Onset with ptosis (n, %) | 0.114 | ||
Unilateral ptosis | 4 (40.0%) | 14 (73.7%) | |
Bilateral ptosis | 6 (60.0%) | 5 (26.3%) | |
Onset with diplopia (n, %) | 5 (50.0%) | 8 (42.1%) | 0.714 |
Thymic abnormalities (thymoma/hyperplasia), (n, %) | 2 (20.0%) | 2 (10.5%) | 0.592 |
Thymectomy before treatment (n, %) | 0 | 2 (10.5%) | 0.532 |
Autoimmune thyroid diseases (n, %) | 5 (50.0%) | 3 (15.8%) | 0.083 |
QMG score at baseline, (median [IQR]) | |||
Ocular QMG score | 6.5 (5.5, 8) | 4 (3, 6) | 0.010* |
QMG score for diplopia | 3 (2.25, 3) | 3 (0, 3) | 0.198 |
QMG score for ptosis | 3 (3, 3) | 2 (1, 3) | 0.013* |
QMG score for eyelid closure | 1.5 (0.75, 2) | 1 (0, 2) | 0.183 |
QMG score at discharge, (median [IQR]) | |||
Ocular QMG score | 3 (1, 4.25) | 4 (3, 5) | 0.129 |
QMG score for diplopia | 2 (0, 3) | 3 (0, 3) | 0.661 |
QMG score for ptosis | 1 (0, 1) | 1 (1, 3) | 0.054 |
QMG score for eyelid closure | 0.5 (0, 1) | 1 (0, 2) | 0.218 |
Period of IVMP therapy (days) | 6 (5, 7) | 7 (6, 9) | 0.131 |
Initial dose of 500 mg/d in IVMP therapy (n, %) | 5 (50.0%) | 5 (26.3%) | 0.244 |
Total dose of MP in IVMP therapy (n, %) | 0.132 | ||
≦3000 mg | 6 (60.0%) | 4 (21.1%) | |
3000 mg < , ≦4250 mg | 2 (20.0%) | 10 (52.6%) | |
4250 mg < , ≦5500 mg | 2 (20.0%) | 5 (26.3%) | |